Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback